Corbus Pharmaceuticals posted a $37.8 million Q3 2026 net loss amid a $15.0 million milestone payment, while maintaining $115.3 million in cash to fund operations into 2028.
The Q3 2026 report shows a wider net loss of $37.8 million ($1.81 per share) versus $23.3 million a year ago, driven by a $15.0 million development milestone under the CSPC licensing agreement. Offsetting this, the company initiated dosing in its TEMPO-1 Phase 3 study of sutantatug envedotin and reported positive topline data from CANYON-1 for CRB-913 in obesity, with $115.3 million in cash funding operations into 2028. Clinical milestones advance the pipeline but the loss widened and no revenue was reported.
Corbus Pharmaceuticals reported a net loss of $37.8 million for the third quarter of 2026, compared to $23.3 million in the same period last year. The increased loss was driven by a $15.0 million development milestone payment related to its CSPC licensing agreement. Despite the financial results, the company reached key clinical milestones, including initiating the TEMPO-1 Phase 3 study and reporting positive topline data for its obesity candidate, CRB-913.
The company reported a net loss of approximately $37.8 million, or $1.81 per share, versus a loss of approximately $23.3 million, or $1.90 per share, in the same quarter of 2025.
The company had $115.3 million in cash, cash equivalents, and investments as of September 30, 2026, which it expects to fund operations into 2028 based on current plans.